vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease. Its drug candidates also include TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase 2b clinical trials for the treatment of type 2 diabetes, as well as initiated Phase 1b/2 clinical trials for the treatment of type 1 diabetes; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. vTv Therapeutics Inc. has a license and research agreement with Calithera Biosciences, Inc. to develop and commercialize its hexokinase II inhibitors for therapeutic, prophylactic, preventative, or diagnostic use. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of vTv Therapeutics Holdings LLC.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VTVT
Previous Symbol
CUSIPN/A
Phone336-841-0300
Debt
Debt-to-Equity RatioN/A
Current Ratio0.23
Quick Ratio0.23
Price-To-Earnings
Trailing P/E Ratio-1.19
Forward P/E Ratio-2.16
P/E GrowthN/A
Sales & Book Value
Annual Sales$290,000.00
Price / Sales237.02
Cash FlowN/A
Price / CashN/A
Book Value($1.27) per share
Price / Book-1.57
Profitability
EPS (Most Recent Fiscal Year)($1.67)
Net Income$-16,140,000.00
Net Margins-136.66%
Return on EquityN/A
Return on Assets-67.27%
Miscellaneous
Employees56
Outstanding Shares34,540,000
Market Cap$83.23 million
OptionableNot Optionable
vTv Therapeutics (NASDAQ:VTVT) Frequently Asked Questions
What is vTv Therapeutics' stock symbol?
vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."
How were vTv Therapeutics' earnings last quarter?
vTv Therapeutics Inc (NASDAQ:VTVT) released its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.12) by $0.06. The biotechnology company earned $3.38 million during the quarter, compared to the consensus estimate of $2.06 million. View vTv Therapeutics' Earnings History.
When is vTv Therapeutics' next earnings date?
What price target have analysts set for VTVT?
6 equities research analysts have issued twelve-month price objectives for vTv Therapeutics' stock. Their forecasts range from $4.00 to $28.00. On average, they expect vTv Therapeutics' share price to reach $15.60 in the next twelve months. This suggests a possible upside of 683.9% from the stock's current price. View Analyst Price Targets for vTv Therapeutics.
What is the consensus analysts' recommendation for vTv Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for vTv Therapeutics in the last year. There are currently 5 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for vTv Therapeutics.
Has vTv Therapeutics been receiving favorable news coverage?
Headlines about VTVT stock have trended somewhat positive this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. vTv Therapeutics earned a media sentiment score of 1.1 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an impact on the stock's share price in the next several days.
Are investors shorting vTv Therapeutics?
vTv Therapeutics saw a drop in short interest in October. As of October 31st, there was short interest totalling 1,142,091 shares, a drop of 37.1% from the October 15th total of 1,815,417 shares. Based on an average daily volume of 2,706,244 shares, the short-interest ratio is presently 0.4 days. Approximately 145.5% of the company's shares are short sold. View vTv Therapeutics' Current Options Chain.
Who are some of vTv Therapeutics' key competitors?
Some companies that are related to vTv Therapeutics include ZIOPHARM Oncology (ZIOP), Minerva Neurosciences (NERV), Seres Therapeutics (MCRB), Kalvista Pharmaceuticals (KALV), resTORbio (TORC), TapImmune (MRKR), Adamas Pharmaceuticals (ADMS), Merus (MRUS), Aratana Therapeutics (PETX), Aclaris Therapeutics (ACRS), Keryx Biopharmaceuticals (KERX), Concert Pharmaceuticals (CNCE), MannKind (MNKD), Geron (GERN) and Albireo Pharma (ALBO).
Who are vTv Therapeutics' key executives?
vTv Therapeutics' management team includes the folowing people:
- Mr. Jeffrey B. Kindler, Exec. Chairman (Age 62)
- Mr. Stephen L. Holcombe, Pres & CEO (Age 61)
- Mr. Rudy C. Howard CPA, B.A., CPA, Exec. VP & CFO (Age 60)
- Dr. Larry Douglas Altstiel, Former Exec. VP & Chief Medical Officer (Age 68)
- Dr. Carmen Valcarce Ph.D., Chief Scientific Officer & Exec. VP
When did vTv Therapeutics IPO?
(VTVT) raised $125 million in an initial public offering (IPO) on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.
How do I buy shares of vTv Therapeutics?
Shares of VTVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is vTv Therapeutics' stock price today?
One share of VTVT stock can currently be purchased for approximately $1.99.
How big of a company is vTv Therapeutics?
vTv Therapeutics has a market capitalization of $83.23 million and generates $290,000.00 in revenue each year. The biotechnology company earns $-16,140,000.00 in net income (profit) each year or ($1.67) on an earnings per share basis. vTv Therapeutics employs 56 workers across the globe.
What is vTv Therapeutics' official website?
How can I contact vTv Therapeutics?
vTv Therapeutics' mailing address is 4170 MENDENHALL OAKS PKWY, HIGH POINT NC, 27265. The biotechnology company can be reached via phone at 336-841-0300 or via email at [email protected]
MarketBeat Community Rating for vTv Therapeutics (NASDAQ VTVT)
MarketBeat's community ratings are surveys of what our community members think about vTv Therapeutics and other stocks. Vote "Outperform" if you believe VTVT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VTVT will underperform the S&P 500 over the long term. You may vote once every thirty days.
